- Tytuł:
- Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax.
- Autorzy:
- Temat:
-
MANTLE cell lymphoma
BRUTON tyrosine kinase
VENETOCLAX - Źródło:
- Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p484-486, 3p
Czasopismo naukowe